TY - JOUR
T1 - High-dose Cytarabine and Mitoxantrone as Salvage Therapy for Refractory Non-Hodgkin's Lymphoma
AU - Wang, Wei Shu
AU - Tzeng, Cheng Hwai
AU - Chiou, Tzeon Jye
AU - Liu, Jin Hwang
AU - Hsieh, Ruey Kuen
AU - Yen, Chueh Chuan
AU - Chen, Po Min
N1 - Funding Information:
This work was kindly supported by a grant from the Tjing-Ling Medical Foundation.
PY - 1997
Y1 - 1997
N2 - High-dose cytarabine alone or in combination with mitoxantrone has been shown to be active against refractory non-Hodgkin's lymphoma in therapeutic trials. We administered these two drugs to 16 patients with advanced and refractory non-Hodgkin's lymphoma. Cytarabine was administered at 3 g/m2 as a 2-h intravenous infusion every 12 h on days 1-4 (8 doses) and mitoxantrone at 6 mg/m2/day as a 1-h intravenous infusion on days 1-5. The clinical efficacy and toxicity were assessed according to the WHO criteria. Five patients (31%, 95% Cl: 8-54%) attained complete remission and two had partial remission. In three of the five complete remission patients, the remission lasted for >4 months. The remaining two patients had complete remission for only 1.3 months. Myelosuppression with subsequent infection was the major toxicity of this regimen. Severe leukopenia (WBC <1000/μl) lasted for an average of 20 days and thrombocytopenia (<25 000/μl) 18 days. Five patients (31%) died of treatment-related complications: neutropenia-associated sepsis in three, pneumonia in one and electrolyte imbalance in one. Nonmyeloid toxicities included alopecia in 100% (19% Gr.2, 75% Gr.3), stomatitis in 88% (13% Gr.2, 31% Gr.3), hepatotoxicity in 38% (6% Gr.2, 6% Gr.3), dermatitis in 31% (19% Gr.2), CNS toxicity in 25% (6% Gr.2, 6% Gr.3), infection in 38% (13% Gr.3, 19% Gr.4) and chemical conjunctivitis in 6% (Gr.2). We conclude that a proportion of refractory non-Hodgkin's lymphoma cases will respond to high-dose cytarabine + mitoxantrone, but that the treatment seems too toxic to be acceptable as salvage therapy for refractory non-Hodgkin's lymphoma.
AB - High-dose cytarabine alone or in combination with mitoxantrone has been shown to be active against refractory non-Hodgkin's lymphoma in therapeutic trials. We administered these two drugs to 16 patients with advanced and refractory non-Hodgkin's lymphoma. Cytarabine was administered at 3 g/m2 as a 2-h intravenous infusion every 12 h on days 1-4 (8 doses) and mitoxantrone at 6 mg/m2/day as a 1-h intravenous infusion on days 1-5. The clinical efficacy and toxicity were assessed according to the WHO criteria. Five patients (31%, 95% Cl: 8-54%) attained complete remission and two had partial remission. In three of the five complete remission patients, the remission lasted for >4 months. The remaining two patients had complete remission for only 1.3 months. Myelosuppression with subsequent infection was the major toxicity of this regimen. Severe leukopenia (WBC <1000/μl) lasted for an average of 20 days and thrombocytopenia (<25 000/μl) 18 days. Five patients (31%) died of treatment-related complications: neutropenia-associated sepsis in three, pneumonia in one and electrolyte imbalance in one. Nonmyeloid toxicities included alopecia in 100% (19% Gr.2, 75% Gr.3), stomatitis in 88% (13% Gr.2, 31% Gr.3), hepatotoxicity in 38% (6% Gr.2, 6% Gr.3), dermatitis in 31% (19% Gr.2), CNS toxicity in 25% (6% Gr.2, 6% Gr.3), infection in 38% (13% Gr.3, 19% Gr.4) and chemical conjunctivitis in 6% (Gr.2). We conclude that a proportion of refractory non-Hodgkin's lymphoma cases will respond to high-dose cytarabine + mitoxantrone, but that the treatment seems too toxic to be acceptable as salvage therapy for refractory non-Hodgkin's lymphoma.
KW - High-dose ara-C
KW - Mitoxantrone
KW - Refractory non-Hodgkin's lymphoma
UR - http://www.scopus.com/inward/record.url?scp=0031156947&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031156947&partnerID=8YFLogxK
U2 - 10.1093/jjco/27.3.154
DO - 10.1093/jjco/27.3.154
M3 - Article
C2 - 9255269
AN - SCOPUS:0031156947
SN - 0368-2811
VL - 27
SP - 154
EP - 157
JO - Japanese Journal of Clinical Oncology
JF - Japanese Journal of Clinical Oncology
IS - 3
ER -
